Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

NCT03817398 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03817398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03817398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 8, 2019
Completion date
September 30, 2026
Enrollment
110 (estimated)
Sites
173

Conditions

As the registry lists them; a condition with its own page is linked.

chronic phase chronic myeloid leukemia, bcr-abl1 positive